Section I: General Topics
1. Transcriptional regulation of Charnolosome through gene/base-editing
2. Charnolosome destabilization induces inflammasome activation
3. Charnolosome in Charnoly Body molecular pathogenesis of gene-manipulated cells and animals
4. Charnolosome and inflammasome in chronic MDR diseases
5. Charnolosome stabilization inhibits inflammasome to confer personalized nanotheranostic benefit in chronic MDR diseases
6. Endogenous, natural, and synthetic antioxidants stabilize charnolosome and its exocytosis to confer theranostic benefit by inflammasome inhibition
7. Charnolosome stability index (stabilized Charnolosome vs activated inflammasome) determines normal cellular function to remain healthy
8. Charnolosome stability index regulates Charnoly Body molecular pathogenesis
9. Nanotheranostic significance of antioxidants in Charnolosome detoxification
10. Theranostic significance of Charnolosome in personalized nanomedicine
11. Environmental toxins and transcriptional regulation of Charnolosome
12. Antioxidants-mediated Charnolosome transcriptional regulation in health and disease
13. Mitochondrial bioenergetics, Charnosome, and theranostic potential of antioxidants
14. Cellular, molecular, and genetic significance of metallothioneins as Charnolosome modulators
15. Pharmacogenomics of metallothioneins and other endogenous, natural, and synthetic antioxidants as CS Regulators in health and disease
16. Environmental pollution and metal ion speciation of metallothioneins
17. Metallothioneins as potential charnolopharmacotherapeutics
18. Antioxidants as Charnolosome stabilizers, charnolophagy enhancers, and intracellular detoxifiers.
19. Charnolosomaging triggers inflammaging to induce charnoptosis, pyroptosis, and ferroptosis in chronic MDR diseases in aging
20. Charnolosome as a theranostic biomarker in cell therapy and nanomedicine
Section II: Special Topics
Part 1: Malnutrition, Stress, Inflammation, Microbial Infections, and Ionizing Radiation Injuries
21. Charnolosome in malnutrition
22. Charnolosome in stress
23. Charnolosome in inflammation
24. Charnolosome in microbial infections
25. Charnolosome in ionizing radiation injuries
Part 2: Congenital & Metabolic Diseases
26. Charnolosome in congenital diseases
27. Charnolosome in metabolic diseases
28. Charnolosome in hyperlipidemia
29. Charnolosome in obesity
30. Charnolosome in diabetes
31. Charnolosome in hepatic diseases
32. Charnolosome in GIT diseases
Part 3: Multidrug-Resistant Systemic Diseases
33. Charnolosome in skin diseases
34. Charnolosome in musculo-skeletal diseases
35. Charnolosome in pulmonary diseases
36. Charnolosome in cardiovascular diseases
37. Charnolosome in renal diseases
38. Charnolosome in reproductive diseases
Part 4: Neuropsychiatric & Neurodegenerative Diseases
39. Charnolosome in polysubstance abuse
40. Charnolosome in neuropsychiatric diseases
41. Charnolosome in neurodegenerative diseases
42. Charnolosome in Neurodegenerative ¿-Synucleinopathies
43. Charnolosome in Parkinson's Disease
44. Charnolosome in Alzheimer's Disease and other taupathies
45. Charnolosome in stroke & traumatic brain injury
46. Attenuation of Charnolosome-Mediated Neurodegenerative ¿-Synucleinopathies by antioxidants
47. Charnolosome as a novel nanotheranostic biomarker of aging
Part 5: Inflammatory Diseases, Autoimmune Diseases, Cancer, & Infectious Diseases
48. Charnolosome in Inflammatory Diseases
49. Charnolosome in autoimmune diseases
50. Charnolosome in cancer
51. Charnolosome in infectious diseases
Section III: Future Prospects
52. Charnolosomics in nanomedicine (Recent Update)
53. Charnolosome-based disease-specific nanopharmacotherapeutics
54. Physiological, Biochemical, Pharmacological, and Genetic Manipulation of Charnolosome in Personalized Nanotheranostics of Chronic MDR Diseases
55. Transcriptional and translational regulation of Charnolosome in multi-drug resistant malignancies and other chronic diseases
56. Future prospectus of Charnolosome in evidence-based personalized nanotheranostics
